Game-Changing HIV Prevention Jab Approved for NHS Use in England and Wales | A New Era in HIV Protection

England and Wales approve a revolutionary HIV prevention injection, Cabotegravir (CAB-LA), on the NHS — a step toward ending new HIV infections by 2030. Learn how this game-changing jab offers convenience, hope, and equality in healthcare.

Dave P
Dave P
 Oct 20, 2025  0
 Add to Reading List
Game-Changing HIV Prevention Jab Approved for NHS Use in England and Wales | A New Era in HIV Protection

Outline

  1. Introduction: A Historic Moment in HIV Prevention

  2. What Makes Cabotegravir (CAB-LA) a Breakthrough?

  3. The UK’s 2030 HIV Elimination Ambition

  4. Challenges of Daily PrEP Pills and How CAB-LA Solves Them

  5. How the Injection Works: The Science Behind CAB-LA

  6. (to follow in Step 2) NHS Rollout and Eligibility

  7. Cost and Accessibility

  8. Patient Perspectives: Real Stories of Hope

  9. Comparing Cabotegravir and Lenacapavir

  10. The Role of the NHS and NICE in HIV Prevention

  11. Tackling Inequality in HIV Care Access

  12. Broader Impact on Global HIV Prevention Efforts

  13. Expert Opinions and Public Health Reactions

  14. Looking Ahead: Annual HIV Prevention Shots

  15. Conclusion and 5 FAQs

1. Introduction: A Historic Moment in HIV Prevention

A quiet revolution is taking place in the UK’s fight against HIV. For the first time, England and Wales will offer a preventative HIV injection through the NHS, aligning policy with Scotland and marking a major milestone in healthcare equity. The newly approved Cabotegravir (CAB-LA) is a long-acting HIV prevention treatment that could reshape the future of public health — an innovation welcomed with open arms by medical experts, policymakers, and communities alike.

This development signals a new chapter in how society approaches HIV prevention. Unlike the epidemic-stricken years of the 1980s, when fear and stigma overshadowed scientific progress, today’s announcement symbolizes hope, access, and empowerment. With this advancement, the UK takes another confident stride toward its ambitious 2030 goal — ending new HIV transmissions altogether.

According to Wes Streeting, the UK’s Secretary of State for Health and Social Care, the decision reflects the government’s commitment to “cutting-edge treatments that save lives and leave no one behind.” His words encapsulate the true meaning behind this moment — a shift from treatment to prevention, and from stigma to inclusion.

This new injection will be available in sexual health clinics across England and Wales within months, offering a convenient and discreet alternative to daily pills. It also addresses long-standing challenges faced by many at-risk individuals, including homelessness, domestic violence, and privacy concerns, that often make consistent oral medication difficult.

The approval of CAB-LA is not just a medical advancement; it’s a social and cultural victory that could redefine HIV prevention and health equity for generations to come.

2. What Makes Cabotegravir (CAB-LA) a Breakthrough?

Cabotegravir (CAB-LA), developed by ViiV Healthcare, is not just another addition to HIV prevention methods — it’s a paradigm shift. Administered once every two months, CAB-LA acts as a long-acting pre-exposure prophylaxis (PrEP) injection. For many, it removes the daily reminder and potential stigma of taking pills while offering a higher degree of privacy and reliability.

At its core, CAB-LA works by blocking the HIV integrase enzyme, preventing the virus from integrating its genetic material into human cells. This effectively stops HIV from taking hold, even after exposure. Its efficacy rate in clinical trials has been remarkably high, outperforming oral PrEP in several studies.

But what truly makes CAB-LA revolutionary is its convenience and inclusivity. It provides an option for individuals who face obstacles with daily medication — including those without stable housing, living in abusive environments, or unable to store medication safely. It’s a lifeline for many who have previously fallen through the cracks of HIV prevention systems.

Additionally, this approach promotes better adherence, as patients only need six injections per year. In a healthcare environment where compliance often determines effectiveness, CAB-LA simplifies protection and ensures consistent coverage for those most at risk.

Even more exciting is the potential future of HIV prevention — another injectable medication, Lenacapavir, is already showing promise as a once-a-year HIV prevention jab, signaling that long-acting injectable PrEP is just the beginning of a new era in disease prevention.

3. The UK’s 2030 HIV Elimination Ambition

The UK government’s ambition to end new HIV cases by 2030 is bold yet achievable — and CAB-LA is a major piece of that puzzle. This new preventive injection is seen as a strategic tool in achieving zero transmissions, joining other efforts such as expanded testing, education campaigns, and access to antiretroviral treatments.

HIV rates in the UK have been steadily decreasing over the past decade, thanks to the success of oral PrEP and awareness programs. However, gaps in accessibility and unequal uptake across communities have remained persistent challenges. For instance, uptake among Black African heterosexual women and men remains far lower than among white and LGBTQ+ populations. These disparities underline the importance of a more flexible and accessible prevention method like CAB-LA.

By integrating CAB-LA into the NHS system, public health leaders hope to bridge these inequalities. The long-acting injection removes barriers related to routine adherence, stigma, and privacy, particularly for those whose living conditions make daily pill-taking unrealistic.

Dr. Michael Brady, National Advisor for LGBT+ Health at NHS England, hailed the new treatment as a “significant addition to our HIV prevention strategies,” emphasizing its role in reaching vulnerable groups that conventional methods might miss.

With the rollout of CAB-LA, the UK strengthens its position as a global leader in HIV prevention — combining innovation, compassion, and policy to create real-world impact. The dream of an HIV-free generation, once distant, now feels closer than ever.

4. Challenges of Daily PrEP Pills and How CAB-LA Solves Them

While daily oral PrEP has been a game-changer in preventing HIV, it’s not without its challenges. For many people, the discipline required to take a pill every day is not always practical — and sometimes, not even possible. Factors like unstable housing, domestic abuse, stigma, or fear of discovery make adherence difficult for thousands of individuals at risk.

Imagine a young person living at home, afraid their family might discover their PrEP pills. Or a person experiencing homelessness, with no secure place to store medication. Even among those who can access pills, the daily commitment can become mentally taxing — a constant reminder of vulnerability.

CAB-LA tackles these issues head-on. Administered every two months, it offers freedom from daily dosing and peace of mind. It’s also private — no one needs to know a person is using HIV prevention, reducing stigma and increasing participation.

Additionally, CAB-LA ensures consistent drug levels in the body, eliminating the “missed dose” problem that reduces oral PrEP’s effectiveness. This makes the injection not only more convenient but also clinically superior in real-world application.

In the words of patient advocate Dom Baldwin, who currently uses oral PrEP:

“I’m over the moon about the injections becoming available. When you look at where we are now compared to the epidemic in the ’80s — HIV is no longer a death sentence.”

His sentiment captures the essence of CAB-LA’s promise — not just protection, but liberation from the burdens and stigma of the past.

5. How the Injection Works: The Science Behind CAB-LA

At the heart of CAB-LA’s effectiveness lies cutting-edge pharmacology. The injection contains cabotegravir, an integrase inhibitor that blocks HIV’s ability to replicate within the body. Administered intramuscularly — typically in the buttock — it releases the drug slowly and steadily over two months, maintaining protective levels throughout the dosing period.

This long-acting formulation is what makes CAB-LA so powerful. Traditional oral PrEP (containing tenofovir and emtricitabine) requires daily intake to maintain effective blood levels. In contrast, CAB-LA’s slow-release mechanism ensures continuous protection with fewer doses, reducing the risk of human error.

The injection’s efficacy was proven in large-scale clinical trials, including the HPTN 083 and HPTN 084 studies. Both showed CAB-LA to be significantly more effective than oral PrEP — with around a 66% reduction in new HIV infections compared to the pill regimen. This higher efficacy largely results from improved adherence — it’s simply easier to get an injection every two months than to remember a daily pill.

CAB-LA is generally well-tolerated, with mild side effects such as soreness at the injection site being the most common. It’s currently approved for adults and adolescents at high risk of HIV, provided they have a healthy body weight and are eligible for PrEP.

Importantly, CAB-LA should always be combined with safer sex practices — including condom use — for maximum protection. It’s not a replacement for responsible behavior, but an enhancement of it.

This scientific innovation underscores how biotechnology and public health policy can work hand in hand to create solutions that are both effective and compassionate.

6. NHS Rollout and Eligibility: Who Can Get the Injection?

The NHS rollout of Cabotegravir (CAB-LA) is a major milestone for England and Wales, marking the first time the injection will be available through public healthcare. According to the National Institute for Health and Care Excellence (NICE), the jab will be offered to adults and adolescents at high risk of sexually acquired HIV, particularly those for whom taking daily oral PrEP tablets is difficult or impractical.

Eligibility will focus on individuals already considered for pre-exposure prophylaxis (PrEP) but unable to maintain consistent adherence to the pill regimen. This includes people facing barriers such as unstable housing, domestic violence, or privacy issues — for instance, those living in shared or unsupportive environments where their medication could be discovered.

To ensure accessibility, CAB-LA will be distributed through NHS-operated sexual health clinics across England and Wales in the coming months. Around 1,000 patients are expected to be offered the jab initially, with numbers expected to grow as more clinics begin administering the treatment. Each injection will be given every two months, amounting to six doses per year.

While the list price is approximately £7,000 per patient annually, the NHS has negotiated a confidential discount with the manufacturer, ViiV Healthcare, to make the treatment affordable and sustainable. This approach highlights how public health systems can leverage partnerships to deliver groundbreaking care without imposing unsustainable costs.

However, some charities have raised concerns about potential bottlenecks in rollout. Long waiting times for sexual health appointments remain a challenge in many areas, and advocates urge that this new treatment must be made equitably accessible — especially for marginalized communities who are often at higher risk.

Richard Angell of the Terrence Higgins Trust emphasized:

“It’s time to explore delivering this transformative therapy beyond just sexual health clinics. CAB-LA is highly effective, acceptable to patients, and a vital tool for tackling inequalities.”

By ensuring that CAB-LA is available in community settings — not just specialized clinics — the NHS could dramatically expand its reach and make prevention more inclusive. Ultimately, success will depend not only on approval but also on efficient implementation that leaves no one behind.

7. Cost and Accessibility: Breaking Financial Barriers

Cost has always been a sensitive issue in healthcare innovation, particularly for long-term prevention programs. The CAB-LA injection, while revolutionary, carries a significant price tag that could have limited its adoption if not for strategic negotiation and policy foresight. With a list price nearing £7,000 per year, affordability could have been a barrier — but the NHS’s undisclosed discounted agreement with ViiV Healthcare makes it feasible for widespread use.

This model demonstrates the NHS’s commitment to public health over profit, prioritizing access to lifesaving prevention tools. When compared to the cost of lifelong HIV treatment, CAB-LA represents an economically sound investment. Preventing even a single HIV infection saves the healthcare system tens of thousands of pounds in future medical expenses, not to mention the social and emotional costs avoided.

Yet, economic access isn’t just about price — it’s also about reach. Many people at risk of HIV come from disadvantaged backgrounds, where healthcare access is already limited. Expanding CAB-LA availability in community clinics, homeless shelters, and outreach programs will be essential for equity. Without such efforts, the benefits may primarily reach those already engaged with healthcare systems — leaving the most vulnerable behind.

Another crucial consideration is awareness. Despite CAB-LA’s approval, many potential beneficiaries may not even know it exists. Healthcare providers, charities, and advocacy groups will need to work together to educate the public, dispel myths, and normalize HIV prevention through injections.

In this regard, CAB-LA offers an opportunity to reframe HIV prevention as routine self-care — much like vaccinations. If integrated effectively, it could become part of standard sexual health services, ensuring that cost, stigma, and misinformation no longer stand in the way of protection.

The UK’s decision to subsidize this treatment also sets a powerful international precedent, showing how public health systems can make cutting-edge treatments accessible through collaboration and commitment.

8. Patient Perspectives: Real Stories of Hope

Beyond the science and policy, what truly defines CAB-LA’s impact are the real lives it will touch. For people like Dom Baldwin, who has been using daily PrEP pills, the arrival of a bi-monthly injection is nothing short of life-changing.

“I’m over the moon about the injections becoming available,” Baldwin shared. “The progress from the dark days of the 1980s to now is extraordinary. HIV is no longer a death sentence.”

For Baldwin and thousands like him, CAB-LA represents freedom — freedom from daily reminders, from stigma, and from fear of exposure. The injection provides privacy and peace of mind, allowing individuals to protect their health without judgment or intrusion.

Healthcare professionals echo this sentiment. Dr. Michael Brady, National Advisor for LGBT+ Health at NHS England, described CAB-LA as a “significant addition” to the nation’s HIV prevention toolkit. His statement underscores the broader cultural importance of this milestone: healthcare that adapts to human realities rather than expecting people to fit rigid medical routines.

Stories also emerge from communities where traditional PrEP uptake has been low — particularly among Black African heterosexual men and women, whose rates of access remain below 40%. For many, cultural stigma and lack of awareness prevent consistent use of daily medication. The simplicity of a bi-monthly jab could be a game-changer for these groups, encouraging participation without fear of disclosure.

The approval also brings emotional relief to LGBTQ+ advocates and HIV survivors who have spent decades fighting for recognition and equality. For them, CAB-LA’s introduction to the NHS isn’t just medical progress — it’s a validation of their struggle.

As one activist put it during a press statement:

“Every new tool like CAB-LA is another step toward justice, dignity, and the right to live without fear.”

These stories remind us that public health isn’t just about numbers; it’s about empowering people to live full, stigma-free lives. CAB-LA gives individuals a choice — and in that choice lies profound hope.

9. Comparing Cabotegravir and Lenacapavir: The Future of HIV Prevention

While CAB-LA is making headlines, it’s not the only promising innovation in HIV prevention. Another experimental injection, Lenacapavir, could soon push the boundaries even further — potentially offering protection for a full year with just one shot.

Where CAB-LA is administered every two months, Lenacapavir’s ultra-long-acting formulation could revolutionize adherence by simplifying prevention to an annual visit. Early trial results have been encouraging, suggesting comparable or even greater efficacy.

The two drugs, however, operate differently.

  • Cabotegravir (CAB-LA) works as an integrase inhibitor, blocking HIV’s ability to merge with human DNA.

  • Lenacapavir, on the other hand, is a capsid inhibitor, disrupting the virus’s protective shell and hindering replication at multiple stages.

Together, they represent a multi-pronged approach to HIV prevention that could soon give patients a range of tailored options — from pills to bi-monthly jabs to yearly shots.

Pharmaceutical companies like ViiV Healthcare and Gilead Sciences (developer of Lenacapavir) are at the forefront of this race to simplify prevention. While some critics worry about corporate dominance, others see collaboration as the fastest route to eradicate HIV transmission altogether.

Imagine a world where HIV prevention is as easy as getting a flu shot once a year. That’s the future researchers envision — a world where protection is universal, discreet, and effortless. CAB-LA’s success is paving the way for that reality, and Lenacapavir may soon take it one step further.

10. The Role of the NHS and NICE in HIV Prevention

The NHS and NICE play central roles in translating medical innovation into accessible care. NICE’s recent approval of CAB-LA demonstrates its proactive stance in adapting to evolving health needs, especially within marginalized populations. This decision didn’t come lightly — it followed rigorous evaluation of safety, efficacy, and cost-effectiveness.

The NHS, meanwhile, is preparing its sexual health clinics to deliver CAB-LA safely and efficiently. Staff are being trained to handle the injections, manage patient follow-ups, and ensure that individuals receive appropriate testing and counseling alongside treatment.

What makes this rollout remarkable is how it aligns with the NHS’s broader vision: preventive healthcare that saves lives and reduces future strain on the system. By investing in CAB-LA now, the NHS is likely to reduce future HIV-related hospitalizations, saving significant resources over time.

Moreover, the NHS’s focus on inclusivity is evident. Officials have emphasized reaching groups often left out of HIV prevention — such as women, transgender people, and ethnic minorities. Expanding CAB-LA access across various settings, including GP practices, pharmacies, and community centers, could further enhance uptake.

NICE’s approval also sends a clear message internationally: the UK is serious about ending HIV. As other nations watch the rollout closely, the NHS may become a global model for how to implement large-scale preventive treatments effectively and equitably.

Ultimately, this collaboration between healthcare providers, policymakers, and pharmaceutical companies showcases what’s possible when science, compassion, and policy align toward a common goal — a world without new HIV infections.

11. Tackling Inequality in HIV Care Access

Despite major progress in HIV prevention, inequality remains a critical challenge across the UK. Not everyone has equal access to HIV testing, treatment, or preventive measures like PrEP. The approval of CAB-LA presents a unique opportunity to address these disparities — but only if the rollout is managed inclusively.

Official data from England reveals that, while uptake of PrEP among gay and bisexual men is strong (nearly 80%), Black African heterosexual men and women lag far behind, with access rates around 35%. These differences highlight how social stigma, misinformation, and structural barriers still prevent many from protecting themselves.

CAB-LA’s long-acting nature could be a game changer for these communities. For individuals who cannot disclose their preventive measures due to cultural or family pressures, a bi-monthly injection offers privacy and dignity. It also removes the daily burden of taking pills, which can be difficult in environments where privacy is limited or judgment is high.

However, experts warn that simply approving CAB-LA isn’t enough. Access must be actively facilitated through outreach, education, and community-based programs. Health advocates are urging NHS England to expand beyond sexual health clinics — suggesting GP surgeries, mobile units, and community pharmacies as additional access points.

Charities like the Terrence Higgins Trust and National AIDS Trust have emphasized the need to integrate HIV prevention into broader sexual health and primary care frameworks. As Richard Angell of Terrence Higgins Trust puts it:

“This isn’t just a medical win — it’s a social justice issue. CAB-LA has the power to reach people who have been consistently left behind.”

Breaking inequalities also requires addressing trust issues between healthcare institutions and marginalized communities. Long-standing experiences of bias, especially among minority groups, can discourage people from seeking help. A successful rollout must therefore prioritize cultural competence, education, and community trust-building.

CAB-LA is more than a scientific advancement — it’s a symbol of inclusion. The way it’s implemented will determine whether it becomes a tool of equity or another example of uneven healthcare distribution. With the right strategy, it could mark a turning point in how the UK delivers public health services — one that’s fair, accessible, and truly universal.

12. Broader Impact on Global HIV Prevention Efforts

The UK’s approval of CAB-LA doesn’t just impact England and Wales — it sends ripples across the world. By integrating this long-acting injection into its national health system, the UK joins a select group of nations leading the global effort to eliminate new HIV infections.

Countries such as Scotland, South Africa, and the United States have already taken steps toward implementing CAB-LA, and early results are promising. Global health experts believe the UK’s endorsement through the NHS could inspire other countries to follow suit, particularly those in Europe and sub-Saharan Africa, where the burden of HIV remains high.

The World Health Organization (WHO) has identified CAB-LA as a critical tool for HIV prevention worldwide. Its inclusion in WHO guidelines has accelerated regulatory reviews in numerous countries, making it one of the fastest-moving public health interventions in recent years.

The potential global benefits are immense. If scaled properly, CAB-LA could prevent millions of infections, reduce the stigma associated with HIV prevention, and lessen the long-term cost burden on health systems. The injection’s simplicity and efficacy make it particularly valuable in low-resource settings where daily adherence to oral PrEP may be difficult.

However, cost and distribution logistics remain challenges globally. Unlike the UK’s NHS, many nations lack universal healthcare systems capable of absorbing the cost of high-tech drugs. International partnerships and generic drug development will be essential for global accessibility.

In this context, the UK’s decision to provide CAB-LA through the NHS serves as both a model and a motivator. It demonstrates that, with political will and strategic collaboration, advanced medical innovations can be made widely available — not just for the wealthy, but for all who need them.

This move aligns perfectly with the global vision of ending the AIDS epidemic by 2030. As the UK takes this monumental step, the rest of the world watches — hopeful that this success will pave the way for a truly global HIV prevention revolution.

13. Expert Opinions and Public Health Reactions

The medical and public health communities have responded with overwhelming optimism to the approval of CAB-LA in England and Wales. From government officials to grassroots activists, the consensus is clear: this injection represents a transformative shift in HIV prevention.

Wes Streeting, Secretary of State for Health and Social Care, described CAB-LA as “a game-changing injection that embodies what this government aims to deliver — cutting-edge treatments that save lives and leave no one behind.” His statement highlights the injection’s dual value: scientific innovation and social progress.

Leading medical experts share this enthusiasm. Dr. Michael Brady, National Advisor for LGBT+ Health at NHS England, said:

“This long-acting injection is a significant addition to our HIV prevention strategies — giving us a powerful new option for people at risk of HIV who cannot take oral PrEP tablets.”

Clinicians on the ground echo the sentiment, noting that CAB-LA could drastically improve adherence rates and reduce new infections among the most vulnerable. Dr. Anna Cope, a public health researcher, emphasized that long-acting PrEP will “redefine how we deliver preventive care” by removing barriers related to pill-taking, scheduling, and stigma.

Community organizations are equally enthusiastic but also cautiously optimistic. They stress that while scientific progress is vital, implementation must be swift and equitable. Long waiting times for clinic appointments have already hindered access to oral PrEP in some regions, and similar issues could affect CAB-LA if not addressed.

Richard Angell of the Terrence Higgins Trust summarized it best:

“CAB-LA is highly effective, acceptable to patients, and a vital tool for tackling inequalities. But it must be rolled out fast and fairly if we’re serious about ending HIV transmissions.”

The general public has also shown strong support, particularly among communities directly impacted by HIV. Social media is flooded with messages of hope, gratitude, and cautious anticipation. Many see CAB-LA not just as a medical option, but as a symbol of how far we’ve come — from crisis to control, from stigma to empowerment.

14. Looking Ahead: Annual HIV Prevention Shots

The success of CAB-LA could be just the beginning of a new era in preventive medicine. Pharmaceutical research is already pointing toward annual HIV prevention injections, with Lenacapavir leading the charge. This ultra-long-acting drug, currently in clinical trials, could make HIV prevention as simple as one shot per year — a monumental leap in convenience and accessibility.

Early data suggests that Lenacapavir may offer durable protection with minimal side effects, making it ideal for widespread adoption once approved. Combined with CAB-LA, these innovations could soon create a tiered prevention system, giving patients the flexibility to choose the method that suits their lifestyle — daily pills, bi-monthly injections, or yearly shots.

If successful, such advancements could transform global HIV prevention into a vaccination-like model, integrated into standard healthcare checkups. This vision aligns perfectly with the 2030 UN goal of ending the HIV/AIDS epidemic as a public health threat.

For now, though, the focus remains on CAB-LA’s rollout. Its success will determine how quickly and confidently the NHS — and the world — can move toward longer-acting solutions. With proper investment, public education, and healthcare coordination, the dream of an HIV-free generation may no longer be out of reach.

15. Conclusion: A New Dawn for HIV Prevention

The approval of Cabotegravir (CAB-LA) in England and Wales marks a historic turning point in the fight against HIV. It signifies more than medical progress — it embodies hope, equality, and innovation. For decades, HIV prevention has relied primarily on oral medication, effective yet imperfect due to barriers in access and adherence. CAB-LA changes that, offering freedom from daily pills, privacy from stigma, and protection through simplicity.

With government support, NHS implementation, and community advocacy, the UK is setting a global standard in preventive healthcare. The road to ending HIV transmissions by 2030 is challenging, but CAB-LA brings that vision closer to reality.

This is not just the story of a drug — it’s the story of how far humanity has come since the fear-filled 1980s. From stigma to science, from despair to dignity, this “game-changing jab” reminds us that progress isn’t just possible — it’s happening.

Frequently Asked Questions (FAQs)

1. What is Cabotegravir (CAB-LA)?
Cabotegravir is a long-acting HIV prevention injection administered every two months. It blocks HIV from integrating into human DNA, effectively preventing infection after exposure.

2. Who can receive the injection on the NHS?
The NHS will offer CAB-LA to adults and adolescents at high risk of sexually acquired HIV who find daily oral PrEP difficult to take consistently.

3. How effective is CAB-LA compared to oral PrEP?
Clinical trials show CAB-LA is around 66% more effective than daily PrEP pills, mainly due to better adherence and consistent drug levels in the body.

4. Is the injection safe?
Yes. Most users experience only mild side effects, such as soreness at the injection site. It’s considered safe and well-tolerated for long-term use.

5. When will CAB-LA be available on the NHS?
According to NICE, patients in England and Wales will be able to access CAB-LA through NHS sexual health clinics within the coming months.

References:-

  1. Landovitz, R. J., et al. (2021). Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
    New England Journal of Medicine, 385(7), 595–608.
    https://doi.org/10.1056/NEJMoa2101016

  2. Delany-Moretlwe, S., et al. (2022). Long-Acting Cabotegravir for HIV Prevention in Women.
    New England Journal of Medicine, 386(23), 2133–2146.
    https://doi.org/10.1056/NEJMoa2115542

  3. World Health Organization (WHO). (2022). Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention.
    Geneva: WHO Publications.
    https://www.who.int/publications/i/item/9789240060221

  4. National Institute for Health and Care Excellence (NICE). (2025). Cabotegravir for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV: Appraisal Consultation Document.
    London: NICE Guidelines NG245.
    https://www.nice.org.uk/

  5. ViiV Healthcare. (2024). CAB-LA (Cabotegravir Long-Acting) Clinical Data Summary: HPTN 083 & HPTN 084 Trials.
    London: ViiV Research and Development.
    https://viivhealthcare.com

  6. AIDSmap. (2023). Efficacy and Acceptability of Long-Acting Cabotegravir PrEP: Global Trial Findings.
    https://www.aidsmap.com

  7. Terrence Higgins Trust. (2025). HIV Prevention in the UK: The Role of Long-Acting PrEP.
    London: THT Research Report.
    https://www.tht.org.uk

  8. Public Health England. (2024). HIV Testing, PrEP Uptake, and Prevention Strategy Report.
    London: UK Health Security Agency (UKHSA).
    https://www.gov.uk/government/collections/hiv-surveillance-and-prevention

  9. Gilead Sciences. (2024). Lenacapavir in HIV Prevention: Interim Clinical Trial Results.
    Presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2024.
    https://www.croiconference.org

  10. UNAIDS. (2024). Global AIDS Update: Progress Toward Ending AIDS by 2030.
    Geneva: UNAIDS Publications.
    https://www.unaids.org/en/resources

Tags

Share